Asahi Intecc (7747) Q3 2025 earnings summary

Executive summary

• Revenue/net sales for the nine months ended March 2025 rose 13.7% year-over-year to 91,815 million yen, driven by strong Medical Division performance and favorable exchange rates.

• Operating income/profit increased 30.8% year-over-year to 25,715 million yen, reflecting improved margins and higher sales despite increased SG&A and R&D expenses.

• Net income/profit attributable to owners declined 37.6% year-over-year to 8,763 million yen due to significant impairment and valuation losses.

• Comprehensive income dropped 66.4% year-over-year to 5,563 million yen, mainly from negative foreign currency translation adjustments.

Financial highlights

• Gross profit grew 18.6% year-over-year to 62,263 million yen, with margin improving from 65.0% to 67.8% due to higher productivity.

• EBITDA increased 25.4% year-over-year to 33,708 million yen.

• EPS dropped from 51.69 yen to 32.26 yen year-over-year.

• Extraordinary losses totaled 10,730 million yen, mainly from impairment and valuation losses.

• Total assets as of March 31, 2025 were 182,695 million yen, down 8,918 million yen from June 2024, mainly due to a 6,778 million yen decrease in goodwill.

Outlook and guidance

• Full-year net sales forecast revised to 119,160 million yen (up 10.8% year-over-year), with operating profit expected at 28,859 million yen (up 30.4%).

• Profit attributable to owners forecast at 11,314 million yen, a 28.4% decrease year-over-year, reflecting extraordinary losses.

• Annual dividend forecast raised to 24.23 yen per share.